The VSV-EBOVAC Consortium has collaborated in the study “A dose-dependent plasma signature of innate immune responses to the VSV-Ebola vaccine reflects its biological outcomes and safety in Europe and Africa” published in Science Translational Medicine journal.
The rVSV-ZEBOV vaccine, based on the replication-competent recombinant vesicular stomatitis virus (VSV) expressing a Zaire ebolavirus (EBOV) glycoprotein, is currently the only Ebola vaccine with demonstrated efficacy in Phase III clinical trials. This vaccine was used in Guinea during the recent outbreak and has now been shown to be incredibly effective in preventing infection.
The study published today in Science Translational Medicine examined longitudinal plasma samples from vaccine recipients in Europe and Africa to identify a signature of the immune response and adverse events. The signature of monocyte-derived cytokines held true in both cohorts, suggesting that it could also be applied to other vaccine trials to determine immunogenicity and reactogenicity.
Full text link.